We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer has accelerated COVID-19 vaccine production and is on track to distribute 300 million doses in the U.S. before the end of July, said the company’s CEO Albert Bourla. Read More
Sanofi has announced that it will invest $476 million in a multi-vaccine manufacturing facility in Singapore to mass produce vaccines for the Asian market. Read More
In a much-needed development, Johnson & Johnson began delivery of its one-shot COVID-19 vaccine within the EU yesterday as the trade bloc continues to clamor for enough doses to inoculate its 446 million residents. Read More
Biogen and Chinese drugmaker Bio-Thera Solutions have teamed to develop a biosimilar of Roche’s Actemra (tocilizumab), BAT1806, currently being evaluated in phase 3 trials for moderate-to-severe rheumatoid arthritis. Read More
Cidara will get $27 million upfront as part of the deal with Johnson & Johnson and is eligible for up to $753 million in additional payments. Read More
Under the expanded deal, Catalent is dedicating a new high-speed filling line at its Bloomington site to vaccine production starting next month. Read More
Novartis has entered into a licensing and development agreement with Cambridge, UK-based Artios Pharma to develop new precision oncology drugs. Read More
Moderna has expanded its existing agreement with Catalent to boost COVID-19 vaccine production at Catalent’s fill-and-finish facility in Bloomington, Ind., to supply the U.S. market. Read More
The U.S. government has stepped in to address a serious manufacturing error at Emergent BioSolutions’ Baltimore, Md., facility that wasted 15 million Johnson & Johnson (J&J) vaccine doses. However, putting J&J in charge of the site and barring production of AstraZeneca (AZ)’s vaccine there isn’t likely to halt AZ’s production schedule, a White House official said Monday. Read More